KimoStineMD
Pediatric Hematology & Oncology • Little Rock, ARProfessor, Pediatrics, University of Arkansas COM
Dr. Stine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Childrens Way
# 512-10
Little Rock, AR 72202Phone+1 501-364-4374Fax+1 501-364-6829
Education & Training
Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1985 - 1989
University of Kansas School of MedicineResidency, Pediatrics, 1982 - 1985- University of Kansas School of MedicineClass of 1982
Certifications & Licensure
AR State Medical License 1991 - 2025
NC State Medical License 1989 - 1992
LA State Medical License 1989 - 1991- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia Start of enrollment: 1998 Mar 01
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Start of enrollment: 2006 Feb 02
- Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsGiroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington
Blood. 2024-02-29 - 9 citationsMicroRNA-34a-5p as a promising early circulating preclinical biomarker of doxorubicin-induced chronic cardiotoxicity.Varsha G Desai, Vikrant Vijay, Taewon Lee, Tao Han, Carrie L Moland
Journal of Applied Toxicology. 2022-09-01 - 6 citationsDoxorubicin-induced delayed-onset subclinical cardiotoxicity in miceVarsha G. Desai, Vikrant Vijay, Tao Han, Carrie L. Moland, Bounleut Phanavanh
Journal of Applied Toxicology. 2021-10-20
Press Mentions
ASH 2020: Update for the Alta Study, a Phase 1/2 Gene Therapy Trial of Giroctocogene Fitelparvovec (SB-525) in Adults with Severe Hemophilia ADecember 18th, 2020
Professional Memberships
- Member
- Member
- American Society of Pediatric Hematology OncologyMember
- Histiocytosis SocietyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
